Abstract:ID 90311 Poster Board 475 The D 2 dopamine receptor (D2R) is a G protein-coupled receptor (GPCR) and a validated drug target for the treatment of many neuropsychiatric disorders, including psychosis. All currently available antipsychotics are antagonists of the D2R; however, all of these drugs exhibit polypharmacology resulting in a plethora of off-target side effects including weight gain, dysphoria, and sedation, among others. A highly-selective D2R antagonist might overcome these pitfalls and increase patient compliance with taking antipsychotic medications. Previously, our lab conducted a high-throughput screen to identify D2R-selective antagonists with reduced activity at other GPCRs. This screen identified a promising hit compound that was chemically optimized into the lead drug candidates, NCGC1360 and NCGC1366. These drug leads have relatively high binding affinities at the D2R (~80 and ~50 nM, respectively), while displaying >100-fold selectivity over the D3R and >24-fold selectivity over the D4R. A β-arrestin recruitment assay revealed even higher D2R selectivity (>100-fold) of these compounds over the D3R and D4R. In a screen against an array of 46 GPCRs, channels, and transporters using radioligand binding assays, NCGC1360 and NCGC1366 only inhibited radioligand binding to the D2R. A functional screen of 168 GPCRs further determined that NCGC1360 and NCGC1366 were exceptionally selective with each compound completely antagonizing β-arrestin recruitment to the D2R with only minor effects at a few other receptors. Schild-type analyses using dopamine-stimulated β-arrestin recruitment revealed that both compounds are competitive antagonists. A comparative molecular docking study using the active structures of both the D2R and D3R showed that NCGC1366 occupies the orthosteric binding pocket of the D2R with extended contacts with residues in extracellular loop 2 (ECL2). The contacts in ECL2 are not conserved between the D2R and D3R, which may confer D2R selectivity. We thus swapped the ECL2 of the D2R and D3R and found that a D2R mutant with the D3R ECL2 exhibited diminished affinity for NCGC1360 and NCGC1366. Conversely, a D3R mutant with the D2R ECL2 exhibited increased affinity for NCGC1360 and NCGC1366, consistent with the molecular docking study. Pharmacokinetic studies of NCGC1360 in mice revealed a half-life of 1.8 hr in plasma and 1 hr in brain with excellent brain penetration. Finally, NCGC1360 was characterized in animal models that are predicative of antipsychotic efficacy and on-target side effects. NCGC1360 dose-dependently decreased amphetamine-induced hyperlocomotion in mice and also rescued deficits in pre-pulse inhibition induced by amphetamine. Importantly, NCGC1360 did not induce catalepsy up to the highest dose tested (10 mg/kg), suggesting that it would not induce extrapyramidal side effects in patients. Taken together, these studies provide support for continuing the development of this scaffold with preclinical and IND-enabling studies. Funded by the National Institutes of Health intramural research program.

β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors

β-arrestin-biased Allosteric Modulator of Neurotensin Receptor 1 Reduces Ethanol Drinking and Responses to Ethanol Administration in Rodents

Shared and Divergent Transcriptomic Regulation in Nucleus Accumbens D1 and D2 Medium Spiny Neurons by Cocaine and Morphine

SR9883 is a novel small-molecule enhancer of α4β2* nicotinic acetylcholine receptor signaling that decreases intravenous nicotine self-administration in rats

Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor

Design of allosteric modulators that change GPCR G protein subtype selectivity

Identification of a Novel Neuropeptide S Receptor Antagonist Scaffold Based on the SHA-68 Core

Non-small-molecule Therapeutics for Drug Addiction: from Pharmacokinetics Modulating to Synthetic Biology

Optimizing positive allosteric modulators to selectively target the high sensitivity 23 nicotinic acetylcholine receptor

Mechanistic Elucidation of Activation/Deactivation Signal Transduction Within Neurotensin Receptor 1 Triggered by 'driver Chemical Groups' of Modulators: A Comparative Molecular Dynamics Simulation.

Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy

Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-Carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.

Characterization of NCGC1360 and NCGC1366 as Highly-Selective D2 Dopamine Receptor Antagonists and Lead Candidates for the Treatment of Neuropsychiatric Disorders

Neuropeptide S receptor ligands: a patent review (2005-2016)

Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Inhibits Heroin Self-Administration Without Depressive Side Effects in Rats

AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects

Small Molecule Modulators of Beta-arrestins

Study on psychoactive substances addiction in psychopharmacological profiles

Positive allosteric modulation of glutamate transporter reduces cocaine-induced locomotion and expression of cocaine conditioned place preference in rats

Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior

N--6-Hexan-1-Amine : A Novel Phenylalkylamine Antagonist of Serotonin 2A Receptors and Voltage-Gated Sodium Channels